This study by Guo et al. (American Journal of Preventive Medicine, 2017) analyzed BRCA mutation testing in women with breast or ovarian cancer and those women who were unaffected.
Retrospective Cohort Study
53,254 adult women who made insurance claims for BRCA mutation testing between 2004-2014 were surveyed. Over the course of the 10 years, tests performed in unaffected women increased from 24.3% to 61.5% (p<0.001). In addition, 60 to 80% of patients did not meet criteria based on family history. In 2004, approximately 75% of women undergoing testing had a history of cancer compared to approximately 40% by the end of the study in 2014. In a potentially high risk group of women due to early onset cancer (20-40 yrs), a greater proportion who underwent testing were unaffected (41.7%) compared to those with a history of cancer (17.6%) which was statistically significant (p<0.001). The authors conclude that there has been a significant shift from testing patients with a personal history of cancer to those who are unaffected. Moreover, they raise the concern that the current infrastructure is not efficient at identifying those at high risk for pathogenic BRCA mutations.
Use of BRCA Mutation Test in the U.S., 2004-2014
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
